Muscle–eye–brain disease

Other names| Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A3 [1]
Muscle–eye–brain disease has an autosomal recessive inheritance.
Specialty| Neurology
Usual onset| Birth or infancy

Muscle–eye–brain (MEB) disease, also known as muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A3 (MDDGA3),[2] is a kind of rare congenital muscular dystrophy (CMD), largely characterized by hypotonia at birth. Patients have muscular dystrophy, central nervous system abnormalities and ocular abnormalities. The condition is degenerative.

MEB is caused by mutations in the POMGnT1 gene, it is congenital and inherited as an autosomal recessive disorder. There is no cure for MEB. Supportive care mainly focuses on symptoms alleviation which varies in different clinical settings. Symptomatic treatment may include physiological therapies, occupational therapies, medications, and surgeries. The life expectancy of patients with MEB is 10-30 years old, although there have been cases with longer lifespans.

## Contents

* 1 Signs and symptoms
* 1.1 Muscle dystrophies
* 1.2 Ocular abnormalities
* 1.3 Central nervous system abnormalities
* 1.4 Physical appearances
* 2 Causes
* 3 Pathophysiology
* 4 Diagnosis
* 4.1 Physical examination
* 4.2 Genetic test
* 4.3 Medical imaging
* 4.4 Muscle biopsy
* 4.4.1 Histological analysis
* 4.4.2 Enzymatic assay
* 4.4.3 Immunochemistry
* 4.5 Difficulties
* 5 Management
* 6 Prognosis
* 7 Epidemiology
* 8 History
* 9 References

## Signs and symptoms

The main signs and symptoms of MEB includes:[3]

* Muscle dystrophies: muscle weakness, hypotonia, muscle atrophy
* Ocular abnormalities: lack of visual response, severe myopia, glaucoma
* Central nervous system abnormalities: intellectual disability, cortical malformation

### Muscle dystrophies

The most prevalent signs of MEB is infants being born floppy.[4] It refers to the condition of hypotonia. The types of hypotonia found on patients include generalized hypotonia, diffuse hypotonia, congenital hypotonia and the other subtypes.[5] Its cause behind is mainly the severe muscular dystrophy and partly brain abnormalities.[6]

The other signs include joint and/or spinal rigidity, reduced muscle mass, hyporeflexia, muscular contracture, spasticity, muscle atrophy and spinal deformities.[4]

### Ocular abnormalities

Funcdoscopy of the patients with muscle-eye-brain disease. In Fig.A, there is a cataract and in Fig.B optic nerve atrophy, and left retinal dysplasia can be seen. in Fig.C and Fig.D retinal and choroidal pigment epithelium atrophy and optic nerve atrophy can be seen.

Visual problems are often found in people with MEB. Patients have low visual acuity and fail to fixate to the visual stimuli. Depends on the severity, some display no visual response, some can response to light and some to object.[7]

More than 80% of the patients reported visual impairment.[2] Common problems include glaucoma, myopia, strabismus ("crossed-eye") and optic atrophy which all occurs in 80-99%.[2] Optic atrophy contains poor pigmentation of ocular fundi, thin blood vessels of retina, small optic discs and scleral border and optic coloboma (degeneration of the inferior optic nerve).[3][8] Cataract affects 30% - 79% of individuals.[2] Buphthalmos (enlargement of the eyeball), megalocornea (enlargement of cornea) and nystagmus (uncontrollable eyeball movement) are present in some rare case.[2][8]

Although ocular abnormalities account for the poor vision to a large extent, some of the visual problems is associated with the brain abnormalities.[7]

### Central nervous system abnormalities

MEB impairs the cognition gravely. This is reflected by the abnormal EEG and EMG reading in 80% - 99% individuals.[2] At the same frequency, hydrocephalus present in many cases.[2] The severe form of it is associated with the compression of other nerves and results in more complications.[9]

Clinical features include severe intellectually disability in all aspects. Most individuals have intellectual disabilities of a range of severity.[2][10] Progressive deterioration in behavioral development has been recorded.[8] Epilepsy and seizures are found in 30% - 79% of the affected individuals.[2]

Manifestations in structural malformation are common as well. Hypoplasia of mesencephalon, pons, cerebellum and medulla are often.[11][12] Aplasia may occur on top of hypoplasia. Flattened brainstem, ventriculomegaly, pachygyria, Type II lissencephaly have been reported.[10][12] At the rate between 5% and 29% holoprosencephaly and meningocele occurs in patients too.[2]

### Physical appearances

Distinctive facial features for MEB found are high prominent forehead, bulging eye and narrow temporal regions.[13]

## Causes

Cytogenetic location of the POMGnT 1 gene is 1p34.1.[14]

MEB is caused by mutations of the protein O-linked mannose β1,2-N-acetylglucosaminyltransferase 1 (POMGnT1) gene. Pathogenic variants mutate the gene and lead to dysfunction of the POMGnT1 enzyme.  Currently, there are 14 clinically identified mutations, the locations are dispersed and scattered throughout the POMGnT1 gene.[10][6] Different mutations were observed in MEB patients from different countries, namely Finland, Sweden, Norway, Estonia, USA, Israel, Spain and Italy.[6] From 14 non-Finnish patients, 9 different types of mutation were identified.[6]

The location of the mutation is slightly correlated with the severity of the symptoms in terms of brain structural abnormalities.[10] Mutations close to the 5′ terminus of the POMGnT1 coding region lead to relatively more severe phenotype such as hydrocephalus. Mutations that occurred close to the 3′ terminus shows weaker symptoms.[10]

MEB is an autosomal recessive disease inherited from parents. Patients with MEB have two copies of a pathogenic variant in their gene. There will be a risk of having a child with MEB given that both parents are carriers of a pathogenic variant in their gene. The affected child inherits a mutated copy of the gene from each carrier parent. The chance of inheritance is 1 in 4  when both parents carry the pathogenic variant.[15]

## Pathophysiology

The pathogenesis of MEB is related to an abnormal level of α‐dystroglycan glycosylation. Genetic mutations of the POMGnT1 gene reduced the O-mannosyl glycosylation of α-dystroglycan. The POMGnT1 gene encodes the enzyme POMGnT1, a type II transmembrane protein residing in the Golgi Apparatus.[14] The role of the enzyme POMGnT1 is to catalyse glycosylation specific for alpha-linked terminal mannose, the process where N-acetylglucosamine is added to O-linked mannose of α-dystroglycan.[14] In humans, O-mannosylation is a rare type of glycosylation, occurring in skeletal muscle, brain and nerve glycoproteins.[10] O-mannosylation is used to increase the stability of the interaction between the extracellular basement membrane and α-dystroglycan. Without stabilization, the glycoprotein cannot anchor to the cell, leading to congenital muscular dystrophy (CMD), characterised by severe brain malformations.[16]

## Diagnosis

Medical diagnosis for the MEB usually involves the study of family history, measurement of serum CPK level, molecular testing, muscle biopsy and imaging study.[17]

### Physical examination

People with MEB have distinctive facial dysmorphisms.[18] Rounded forehead, thin and drooping lip, micrognathia, midface retrusion, short nasal bridge are the possible indicative evidence for diagnosis.[2][18] Assessment of motor and mental development, visual ability also provide clues.[citation needed]

### Genetic test

Genetic test can analyze the genome of infants for confirmation of the specific genetic mutation. Mutation in the POMGNT1 is the determinant in the diagnosis of MEB.[19] Several mutations like [c.1539+1G→A], [c.879+5G→T] are the prevalent nucleotide change found in affected people.[18][19] The commonly used practices collect fetal DNA by chronic villus sampling, followed by linkage analysis and direct sequencing to conclude the POMGNT1 gene sequence.[20]

The genome determination helps to distinguish other congenital muscular dystrophies before and after birth. However, only some laboratories provide prenatal genetic test to screen for MEB.[2]

### Medical imaging

File:Brain MRI of patients with muscle-eye-brain disease (cropped).webp Brain MRI of the patients with muscle-eye-brain disease. MRI shows frontal lobe micropolygyria, abnormal white-matter signals in the bilateral frontal region, dysplasia of the brainstem and cerebellum, and cerebellar cysts with abnormal white matter signals.

MEB can be diagnosed with medical imaging by the shared patterns of brain structural abnormalities. Common practice includes magnetic resonance imaging (MRI) and computerized tomography (CT). They can show the enlargement of ventricle, absence or degeneration of septum pellucidum, pachygyric symptoms, abnormalities in corpus collosum, lissencephaly.[21] Fetal MRI and ultrasound are used as a prenatal diagnostic tool if needed to screen for the disease. Observation like general structural malformation in the third trimester suggests congenital muscular dystrophy.[22] Further diagnostic test is required to make confirmation.[citation needed]

Clinically, MRI is preferred over CT scan for its ability to reveal the neuron migration more precisely.[21] The result obtained from CT scan is limited to the size of ventricles and location of white matter whereas only MRI can provide information on cortical problems.

### Muscle biopsy

Muscle biopsy is a means to investigate the muscle tissue. Morphology of muscle cells and other chemical parameters can be used to diagnoses muscle–eye–brian disease.[citation needed]

#### Histological analysis

Direct examination of muscular tissues can proof muscle dystrophy, which can support the potential diagnosis of MEB. Patients are found to have myofibrils round in shape and in markedly various diameters, later nuclei, regenerating fibers and angulated fibers as a result from atrophy.[17][23]

#### Enzymatic assay

The mutation of MEB involves the malfunction of O-mannosyl ß-1,2-N-acetylgucosaminyltransfersase 1. By measuring the enzymatic activity of this protein, the presence of MEB can be affirmed.[17] Fibroblast and lymphoblasts are chosen to be the assayed participants.[24]

#### Immunochemistry

Western-blot (immunoblot) can be used to detect the O-mannosyl ß-1,2-N-acetylgucosaminyltransfersase 1 for diagnosis.[23][25] It helps to evaluate the glycosylation state of the protein which it supposed to do.[citation needed]

### Difficulties

As a subtype of muscular dystrophy-dystroglycanopathy, MEB is often confused with other sub-type including Walker–Warburg syndrome and Fukuyama congenital muscular dystrophy.[17][26] All these 3 diseases share similar clinical presentation and are classified as the Type A(severe).[26] Overlapped findings contain clinical presentation and immunochemistry result.[27] The diagnosis has to make distinction among them. The decisive evidences for MEB are:

| MEB | WWS | FCMD

|
|
|

Epidemiology[17] | Finland  | Worldwide  | Japan
Characteristic result of physical examination
Ocular abnormalities[28] | Progressive myopia with retinal degeneration  | Severe malformations  | Simple myopia and cataract without structural change
Common contractures location [17] | Elbow and knee  | Elbow  | Elbow, knee, ankle and hip
Characteristic result of genetic test
Major defected gene contributor [17] | POMGNT1  | POMT1, POMT2  | FKTN
Minor defected gene contributor[29][30][31] | FKRP, FKTN  | FKRP, FCMD, LARGE, ISPD  | \--
Characteristic result of MRI
Cerebral cortex[32] | Diffused dysplasia  | Diffused cobblestone lissencephaly  | Frontal polymicrogyria
White matter [32] | Uneven T1 and T2 prolongation  | No myelin in cerebrum or cerebellum  | Delayed cerebral myelination
Others
Serum creatine kinase level[8][33][34] | Normal to elevated  | Elevated to high level  | Elevated

MEB: muscle–eye–brain disease

WWS: Walker–Warburg syndrome

FCMD: Fukuyama congenital muscular dystrophy

## Management

There is no current curative treatment for any form of muscle dystrophies and only symptomatic care is available for the patients.[17]

The corresponding supportive care to symptoms is:[33][34]

Symptom  | Corresponding support treatment

|

Contractures  | Physiological therapy and tendon-release surgery if needed
Scoliosis  | Bracing, splinting and corrective surgery such as spinal fixation
Muscle weakness  | Leg braces, wheelchair, occupation therapy
Respiratory problem  | Regular monitoring by spirometry, noninvasive nighttime ventilation, tracheostomy, assisted coughing techniques
Learning disabilities  | Specialized education programs
Seizures  | \-  | Vision problems  | Wear special eyeglasses [7][35]
Nutritional care  | Nasogastric tubes for short-term usage, gastrostomy for chronic need

## Prognosis

MEB has a wide range in severity. Most children with MEB has a life expectancy of 10-30 years. But in some patients with milder type of congenital muscle dystrophies, might have a survival up to more than 70 years being possible.[34] The severity of MEB determines its prognosis. Though the prognosis is associated with the progression of symptoms, supportive care enhances the quality of life and also the life expectancy.[29]

## Epidemiology

The majority of MEB occurrence is reported in the Finnish population. It is estimated to affect 1 in 50,000 newborns in Finland.[15] MEB is also identified outside of Finland, there were cases of suspected MEB in Japan and Korea.[10] However, worldwide distribution is unclear.[10] According to the European Union, the estimated prevalence of MEB in Europe is 0.12 per 100000.[41]

Carrier rates [15] Ethnicity  | Detection Rate  | Carrier Frequency

|
|

Finnish  | >99%  | 1 in 50
General Population  | 88%  | 1 in 500

The frequency of being a carrier of MEB is 1 in 50 in Finland, carriers for MEB commonly shows no signs or symptoms. However, their offsprings will have a higher chance to be affected by MEB.[15]

## History

MEB was first discovered in Finland. In 1978, a patient from Finland showed symptoms including congenital muscular weakness, severe myopia, glaucoma, optical malformation, intellectual disability, retinal hypoplasia, etc.[36] In 1980, 14 more people with similar symptoms were identified in Finland.[37] Similar cases were also published in 1989.[38] The disease was found in Dutch in 1992, 6 people were affected coming from 4 families.[39] After that, more cases were reported outside the Finnish population.[citation needed]

MEB is phenotypically similar to the Walker–Warburg syndrome (WWS), both disorders are congenital muscular dystrophy.  In 1990, Santavuori argued to distinct MEB from WWS, since MEB is specifically involving muscle weakness and there is a relatively long survival for MEB patients.[40] In the same year, Dobyns further examined the relation of WWS and MEB.[41]

In 2001, the cause of MEB was first demonstrated as the mutations in the POMGNT1 gene, causing loss of its function.[42]

## References

1. ↑ "Muscle eye brain disease | Genetic and Rare Diseases Information Center (GARD) – an NCATS Program". https://rarediseases.info.nih.gov/diseases/156/muscle-eye-brain-disease. Retrieved 27 October 2019.
2. ↑ 2.00 2.01 2.02 2.03 2.04 2.05 2.06 2.07 2.08 2.09 2.10 2.11 "Muscle eye brain disease | Genetic and Rare Diseases Information Center (GARD) – an NCATS Program". https://rarediseases.info.nih.gov/diseases/156/index.
3. ↑ 3.0 3.1 Fahnehjelm, Kristina Teär; Ygge, Jan; Engman, Mona-Lisa; Mosskin, Mikael; Santavuori, Pirkko; Malm, Gunilla (2001). "A child with Muscle-Eye-Brain disease". Acta Ophthalmologica Scandinavica 79 (1): 72–75. doi:10.1034/j.1600-0420.2001.079001072.x. ISSN 1600-0420. PMID 11167293.
4. ↑ 4.0 4.1 Haltia, M.; Leivo, I.; Somer, H.; Pihko, H.; Paetau, A.; Kivelä, T.; Tarkkanen, A.; Tomé, F. et al. (1997). "Muscle—eye—brain disease: A neuropathological study". Annals of Neurology 41 (2): 173–180. doi:10.1002/ana.410410208. ISSN 1531-8249. PMID 9029066.
5. ↑ Shenoy, Anant M; Markowitz, Jennifer A; Bonnemann, Carsten G; Krishnamoorthy, Kalpathy; Bossler, Aaron D; Tseng, Brian S (March 2010). "Muscle–Eye–Brain Disease". Journal of Clinical Neuromuscular Disease 11 (3): 124–126. doi:10.1097/CND.0b013e3181c5054d. ISSN 1522-0443. PMID 20215985.
6. ↑ 6.0 6.1 6.2 6.3 Diesen, C (2004-10-01). "POMGnT1 mutation and phenotypic spectrum in muscle–eye–brain disease". Journal of Medical Genetics 41 (10): e115. doi:10.1136/jmg.2004.020701. ISSN 1468-6244. PMID 15466003.
7. ↑ 7.0 7.1 7.2 Pihko, Helena; Lappi, Marjatta; Raitta, Christina; Sainio, Kimmo; Valanne, Leena; Somer, Hannu; Santavuori, Pirkko (January 1995). "Ocular findings in muscle–eye–brain (MEB) disease: a follow-up study". Brain and Development 17 (1): 57–61. doi:10.1016/0387-7604(94)00101-3. ISSN 0387-7604. PMID 7762765.
8. ↑ 8.0 8.1 8.2 8.3 Falsaperla, Raffaele; Praticò, Andrea D.; Ruggieri, Martino; Parano, Enrico; Rizzo, Renata; Corsello, Giovanni; Vitaliti, Giovanna; Pavone, Piero (2016-08-31). "Congenital muscular dystrophy: from muscle to brain". Italian Journal of Pediatrics 42 (1): 78. doi:10.1186/s13052-016-0289-9. ISSN 1824-7288. PMID 27576556.
9. ↑ "O52 Visual evoked potentials and electroretinography in brain-dead patients". Neurophysiologie Clinique/Clinical Neurophysiology 20: 18s. August 1990. doi:10.1016/s0987-7053(05)80490-3. ISSN 0987-7053.
10. ↑ 10.0 10.1 10.2 10.3 10.4 10.5 10.6 10.7 Taniguchi, K. (2003-03-01). "Worldwide distribution and broader clinical spectrum of muscle–eye–brain disease". Human Molecular Genetics 12 (5): 527–534. doi:10.1093/hmg/ddg043. ISSN 1460-2083. PMID 12588800.
11. ↑ Shenoy, Anant M; Markowitz, Jennifer A; Bonnemann, Carsten G; Krishnamoorthy, Kalpathy; Bossler, Aaron D; Tseng, Brian S (March 2010). "Muscle–Eye–Brain Disease". Journal of Clinical Neuromuscular Disease 11 (3): 124–126. doi:10.1097/CND.0b013e3181c5054d. ISSN 1522-0443. PMID 20215985.
12. ↑ 12.0 12.1 Raducu, Madalina; Cotarelo, Rocío P.; Simón, Rogelio; Camacho, Ana; Rubio-Fernández, Marcos; Hernández-Laín, Aurelio; Cruces, Jesús (February 2014). "Clinical Features and Molecular Characterization of a Patient with Muscle–Eye–Brain Disease: A Novel Mutation in the POMGNT1 Gene". Journal of Child Neurology 29 (2): 289–294. doi:10.1177/0883073813509119. ISSN 0883-0738. PMID 24282183.
13. ↑ Santavuori, P.; Leisti, J.; Kruus, S. (1977). "Muscle, Eye and Brain Disease: A New Syndrome". Neuropediatrics 8 (S 01): 553. doi:10.1055/s-0028-1091594. ISSN 0174-304X.
14. ↑ 14.0 14.1 14.2 Reference, Genetics Home. "POMGNT1 gene". https://ghr.nlm.nih.gov/gene/POMGNT1.
15. ↑ 15.0 15.1 15.2 15.3 "Muscle-eye brain disease - Gene : POMGNT1". https://geneaware.clinical.bcm.edu/GeneAware/AboutGeneAware/DiseaseDetails.aspx?DiseaseID=304.
16. ↑ Strahl, Sabine; Lommel, Mark (2009-08-01). "Protein O-mannosylation: Conserved from bacteria to humans". Glycobiology 19 (8): 816–828. doi:10.1093/glycob/cwp066. ISSN 0959-6658. PMID 19429925.
17. ↑ 17.0 17.1 17.2 17.3 17.4 17.5 17.6 17.7 S, Gosal Gurinder; H, Shah Hitesh (March 2011). "Muscle–Eye–Brain Disease; a Rare Form of Syndromic Congenital Muscular Dystrophy". Malaysian Orthopaedic Journal 5 (1): 67–70. doi:10.5704/moj.1103.016. ISSN 1985-2533.
18. ↑ 18.0 18.1 18.2 A, Diesen, C Saarinen, A Pihko, H Rosenlew, C Cormand, B Dobyns, W Dieguez, J Valanne, L Joensuu, T Lehesjoki (October 2004). "POMGnT1 mutation and phenotypic spectrum in muscle–eye–brain disease". Journal of Medical Genetics (BMJ Group) 41 (10): e115. doi:10.1136/jmg.2004.020701. OCLC 679802406. PMID 15466003.
19. ↑ 19.0 19.1 Saredi, S.; Ardissone, A.; Ruggieri, A.; Mottarelli, E.; Farina, L.; Rinaldi, R.; Silvestri, E.; Gandioli, C. et al. (July 2012). "Novel POMGNT1 point mutations and intragenic rearrangements associated with muscle–eye–brain disease". Journal of the Neurological Sciences 318 (1–2): 45–50. doi:10.1016/j.jns.2012.04.008. ISSN 0022-510X. PMID 22554691.
20. ↑ Balci, Burcu; Morris-Rosendahl, Deborah J.; Çelebi, Asli; Talim, Beril; Topalo??lu, Haluk; Dinçer, Pervin (2006). "Prenatal diagnosis of muscle–eye–brain disease". Prenatal Diagnosis 27 (1): 51–54. doi:10.1002/pd.1622. ISSN 0197-3851. PMID 17154333.
21. ↑ 21.0 21.1 Valanne, L.; Pihko, H.; Katevuo, K.; Karttunen, P.; Somer, H.; Santavuori, P. (August 1994). "MRI of the brain in muscle–eye–brain (MEB) disease". Neuroradiology 36 (6): 473–476. doi:10.1007/BF00593687. ISSN 0028-3940. PMID 7991095.
22. ↑ Millichap, J. J.; Nguyen, T.; Ryan, M. E. (2010-05-31). "Teaching NeuroImages: Prenatal MRI of muscle–eye–brain disease". Neurology 74 (22): e101. doi:10.1212/wnl.0b013e3181e0f84b. ISSN 0028-3878. PMID 20513809.
23. ↑ 23.0 23.1 Raducu, Madalina; Cotarelo, Rocío P.; Simón, Rogelio; Camacho, Ana; Rubio-Fernández, Marcos; Hernández-Laín, Aurelio; Cruces, Jesús (2013-11-25). "Clinical Features and Molecular Characterization of a Patient with Muscle–Eye–Brain Disease". Journal of Child Neurology 29 (2): 289–294. doi:10.1177/0883073813509119. ISSN 0883-0738. PMID 24282183. https://digital.csic.es/bitstream/10261/124385/6/POMGNT1 gene.pdf. Retrieved 2019-09-30.
24. ↑ Vajsar, Jiri; Zhang, Wenli; Dobyns, William B.; Biggar, Doug; Holden, Kenton R.; Hawkins, Cynthia; Ray, Peter; Olney, Ann H. et al. (February 2006). "Carriers and patients with muscle–eye–brain disease can be rapidly diagnosed by enzymatic analysis of fibroblasts and lymphoblasts". Neuromuscular Disorders 16 (2): 132–136. doi:10.1016/j.nmd.2005.11.012. ISSN 0960-8966. PMID 16427280.
25. ↑ Geis, Tobias; Marquard, Klaus; Rödl, Tanja; Reihle, Christof; Schirmer, Sophie; von Kalle, Thekla; Bornemann, Antje; Hehr, Ute et al. (2013-09-20). "Homozygous dystroglycan mutation associated with a novel muscle–eye–brain disease-like phenotype with multicystic leucodystrophy". Neurogenetics 14 (3–4): 205–213. doi:10.1007/s10048-013-0374-9. ISSN 1364-6745. PMID 24052401.
26. ↑ 26.0 26.1 Amberger, Joanna; Bocchini, Carol; Hamosh, Ada (2011-04-05). "A new face and new challenges for Online Mendelian Inheritance in Man (OMIM®)". Human Mutation 32 (5): 564–567. doi:10.1002/humu.21466. ISSN 1059-7794. PMID 21472891.
27. ↑ Bertini, Enrico; D'Amico, Adele; Gualandi, Francesca; Petrini, Stefania (December 2011). "Congenital Muscular Dystrophies: A Brief Review". Seminars in Pediatric Neurology 18 (4): 277–288. doi:10.1016/j.spen.2011.10.010. PMID 22172424.
28. ↑ Cormand, Bru; Avela, Kristiina; Pihko, Helena; Santavuori, Pirkko; Talim, Beril; Topaloglu, Haluk; de la Chapelle, Albert; Lehesjoki, Anna-Elina (January 1999). "Assignment of the Muscle–Eye–Brain Disease Gene to 1p32-p34 by Linkage Analysis and Homozygosity Mapping". The American Journal of Human Genetics 64 (1): 126–135. doi:10.1086/302206. ISSN 0002-9297. PMID 9915951.
29. ↑ 29.0 29.1 Wang, Ching H.; Bonnemann, Carsten G.; Rutkowski, Anne; Sejersen, Thomas; Bellini, Jonathan; Battista, Vanessa; Florence, Julaine M.; Schara, Ulrike et al. (December 2010). "Consensus Statement on Standard of Care for Congenital Muscular Dystrophies". Journal of Child Neurology 25 (12): 1559–1581. doi:10.1177/0883073810381924. ISSN 0883-0738. PMID 21078917.
30. ↑ Kang, P. B.; Morrison, L.; Iannaccone, S. T.; Graham, R. J.; Bonnemann, C. G.; Rutkowski, A.; Hornyak, J.; Wang, C. H. et al. (2015-03-31). "Evidence-based guideline summary: Evaluation, diagnosis, and management of congenital muscular dystrophy: Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Issues Review Panel of the American Association of Neuromuscular & Electrodiagnostic Medicine". Neurology 84 (13): 1369–1378. doi:10.1212/WNL.0000000000001416. ISSN 0028-3878. PMID 25825463.
31. ↑ Sparks, Susan E.; Quijano-Roy, Susana; Harper, Amy; Rutkowski, Anne; Gordon, Erynn; Hoffman, Eric P.; Pegoraro, Elena (1993). "Congenital Muscular Dystrophy Overview – ARCHIVED CHAPTER, FOR HISTORICAL REFERENCE ONLY". in Adam, Margaret P.; Ardinger, Holly H.; Pagon, Roberta A. et al.. Congenital Muscular Dystrophy Overview. University of Washington, Seattle. https://www.ncbi.nlm.nih.gov/books/NBK1291/. Retrieved 2019-03-27.
32. ↑ 32.0 32.1 Barkovich, A. J. (September 1998). "Neuroimaging manifestations and classification of congenital muscular dystrophies". AJNR. American Journal of Neuroradiology 19 (8): 1389–1396. ISSN 0195-6108. PMID 9763366.
33. ↑ 33.0 33.1 Kirschner, Janbernd (2013), "Congenital muscular dystrophies", Pediatric Neurology Part III, Handbook of Clinical Neurology, 113, Elsevier, pp. 1377–1385, doi:10.1016/b978-0-444-59565-2.00008-3, ISBN 9780444595652, PMID 23622361, https://linkinghub.elsevier.com/retrieve/pii/B9780444595652000083, retrieved 2019-03-27
34. ↑ 34.0 34.1 34.2 Horrocks, I.; Muntoni, F.; Longman, C.; Joseph, S. (2014-10-01). "G.P.315: Cases of normal to mildly elevated creatine kinase in muscle–eye–brain disease patients and delay in diagnosis" (in English). Neuromuscular Disorders 24 (9): 916. doi:10.1016/j.nmd.2014.06.405. ISSN 0960-8966. https://www.nmd-journal.com/article/S0960-8966(14)00556-2/abstract.
35. ↑ 35.0 35.1 "Error: no `|title=` specified when using {{Cite web}}". https://myriadwomenshealth.com/2014/05/hello-world/.Error:+no+`|title=`+specified when+using+{{[[Template:Cite+web|Cite+web]]}}&rft.atitle=&rft_id=https://myriadwomenshealth.com/2014/05/hello-world/&rfr_id=info:sid/en.wikibooks.org:Medicine:Muscle–eye–brain_disease">
36. ↑ RAITTA, CHRISTINA; LAMMINEN, MAIJA; SANTAVUORI, PIRKKO; LEISTI, JAAKKO (2009-05-27). "Ophthalmological Findings in a New Syndrome with Muscle, Eye and Brain Involvement". Acta Ophthalmologica 56 (3): 465–472. doi:10.1111/j.1755-3768.1978.tb05700.x. ISSN 1755-375X. PMID 581135.
37. ↑ W., Eriksson, Aldur (1980). Population structure and genetic disorders : Mariehamm, Åland Islands, Finland, August 1978. Academic Pr. ISBN 0122414500. OCLC 313921203.
38. ↑ Santavuori, P.; Somer, H.; Sainio, K.; Rapola, J.; Kruus, S.; Nikitin, T.; Ketonen, L.; Leisti, J. (1989). "Muscle–eye–brain disease (MEB)". Brain & Development 11 (3): 147–153. doi:10.1016/S0387-7604(89)80088-9. ISSN 0387-7604. PMID 2751061.
39. ↑ Leyten, Q. H.; Gabreëls, F. J.; Renier, W. O.; Renkawek, K.; ter Laak, H. J.; Mullaart, R. A. (December 1992). "Congenital muscular dystrophy with eye and brain malformations in six Dutch patients". Neuropediatrics 23 (6): 316–320. doi:10.1055/s-2008-1071365. ISSN 0174-304X. PMID 1491751.
40. ↑ Santavuori, P.; Pihko, H.; Sainio, K.; Lappi, M.; Somer, H.; Haltia, M.; Raitta, C.; Ketonen, L. et al. (July 1990). "Muscle–eye–brain disease and Walker–Warburg syndrome". American Journal of Medical Genetics 36 (3): 371–374. doi:10.1002/ajmg.1320360334. ISSN 0148-7299. PMID 2363444.
41. ↑ Dobyns, William B.; Pagon, Roberta A.; Curry, Cynthia J. R.; Greenberg, Frank (July 1990). "Response to Santavuori et al. regarding Walker–Warburg syndrome and muscle–eye–brain disease". American Journal of Medical Genetics 36 (3): 373–374. doi:10.1002/ajmg.1320360335. ISSN 0148-7299.
42. ↑ Yoshida, A.; Kobayashi, K.; Manya, H.; Taniguchi, K.; Kano, H.; Mizuno, M.; Inazu, T.; Mitsuhashi, H. et al. (November 2001). "Muscular dystrophy and neuronal migration disorder caused by mutations in a glycosyltransferase, POMGnT1". Developmental Cell 1 (5): 717–724. doi:10.1016/S1534-5807(01)00070-3. ISSN 1534-5807. PMID 11709191.

0.00

(0 votes)

Original source: https://en.wikipedia.org/wiki/Muscle–eye–brain disease. Read more

|

Retrieved from "https://handwiki.org/wiki/index.php?title=Medicine:Muscle–eye–brain_disease&oldid=4305607"